Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies

Fabrizio Piazza, Steven M. Greenberg, Mario Savoiardo, Margherita Gardinetti, Luisa Chiapparini, Irina Raicher, Ricardo Nitrini, Hideya Sakaguchi, Monica Brioschi, Giuseppe Billo, Antonio Colombo, Francesca Lanzani, Giuseppe Piscosquito, Maria Rita Carriero, Giorgio Giaccone, Fabrizio Tagliavini, Carlo Ferrarese, Jacopo C. Difrancesco

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Objective: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid-related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti-amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA-ri. Methods: We used a novel ultrasensitive technique on patients from a retrospective multicenter case-control study, and evaluated the anti-Aβ autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA-ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble Aβ40, Aβ42, tau, P-181 tau, and APOE genotype were also investigated. Results: During the acute phase of CAA-ri, anti-Aβ autoantibodies were specifically increased and directly correlated with Aβ mobilization, together with augmented tau and P-181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble Aβ and axonal degeneration markers decreased in parallel. Interpretation: Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ. The CSF dosage of anti-Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti-Aβ autoantibodies can be considered as novel potential biomarkers in future amyloid-modifying therapies for the treatment of AD and CAA.

Original languageEnglish
Pages (from-to)449-458
Number of pages10
JournalAnnals of Neurology
Volume73
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Cerebral Amyloid Angiopathy
Amyloid
Autoantibodies
Inflammation
Therapeutics
Cerebrospinal Fluid
Alzheimer Disease
Passive Immunization
Multiple Sclerosis
Case-Control Studies
Immunization
Edema
Biomarkers
Genotype

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation : Implications for amyloid-modifying therapies. / Piazza, Fabrizio; Greenberg, Steven M.; Savoiardo, Mario; Gardinetti, Margherita; Chiapparini, Luisa; Raicher, Irina; Nitrini, Ricardo; Sakaguchi, Hideya; Brioschi, Monica; Billo, Giuseppe; Colombo, Antonio; Lanzani, Francesca; Piscosquito, Giuseppe; Carriero, Maria Rita; Giaccone, Giorgio; Tagliavini, Fabrizio; Ferrarese, Carlo; Difrancesco, Jacopo C.

In: Annals of Neurology, Vol. 73, No. 4, 04.2013, p. 449-458.

Research output: Contribution to journalArticle

Piazza, F, Greenberg, SM, Savoiardo, M, Gardinetti, M, Chiapparini, L, Raicher, I, Nitrini, R, Sakaguchi, H, Brioschi, M, Billo, G, Colombo, A, Lanzani, F, Piscosquito, G, Carriero, MR, Giaccone, G, Tagliavini, F, Ferrarese, C & Difrancesco, JC 2013, 'Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies', Annals of Neurology, vol. 73, no. 4, pp. 449-458. https://doi.org/10.1002/ana.23857
Piazza, Fabrizio ; Greenberg, Steven M. ; Savoiardo, Mario ; Gardinetti, Margherita ; Chiapparini, Luisa ; Raicher, Irina ; Nitrini, Ricardo ; Sakaguchi, Hideya ; Brioschi, Monica ; Billo, Giuseppe ; Colombo, Antonio ; Lanzani, Francesca ; Piscosquito, Giuseppe ; Carriero, Maria Rita ; Giaccone, Giorgio ; Tagliavini, Fabrizio ; Ferrarese, Carlo ; Difrancesco, Jacopo C. / Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation : Implications for amyloid-modifying therapies. In: Annals of Neurology. 2013 ; Vol. 73, No. 4. pp. 449-458.
@article{4122f1a971a147ac8c98182b4f12c265,
title = "Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies",
abstract = "Objective: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid-related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti-amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA-ri. Methods: We used a novel ultrasensitive technique on patients from a retrospective multicenter case-control study, and evaluated the anti-Aβ autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA-ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble Aβ40, Aβ42, tau, P-181 tau, and APOE genotype were also investigated. Results: During the acute phase of CAA-ri, anti-Aβ autoantibodies were specifically increased and directly correlated with Aβ mobilization, together with augmented tau and P-181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble Aβ and axonal degeneration markers decreased in parallel. Interpretation: Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ. The CSF dosage of anti-Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti-Aβ autoantibodies can be considered as novel potential biomarkers in future amyloid-modifying therapies for the treatment of AD and CAA.",
author = "Fabrizio Piazza and Greenberg, {Steven M.} and Mario Savoiardo and Margherita Gardinetti and Luisa Chiapparini and Irina Raicher and Ricardo Nitrini and Hideya Sakaguchi and Monica Brioschi and Giuseppe Billo and Antonio Colombo and Francesca Lanzani and Giuseppe Piscosquito and Carriero, {Maria Rita} and Giorgio Giaccone and Fabrizio Tagliavini and Carlo Ferrarese and Difrancesco, {Jacopo C.}",
year = "2013",
month = "4",
doi = "10.1002/ana.23857",
language = "English",
volume = "73",
pages = "449--458",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation

T2 - Implications for amyloid-modifying therapies

AU - Piazza, Fabrizio

AU - Greenberg, Steven M.

AU - Savoiardo, Mario

AU - Gardinetti, Margherita

AU - Chiapparini, Luisa

AU - Raicher, Irina

AU - Nitrini, Ricardo

AU - Sakaguchi, Hideya

AU - Brioschi, Monica

AU - Billo, Giuseppe

AU - Colombo, Antonio

AU - Lanzani, Francesca

AU - Piscosquito, Giuseppe

AU - Carriero, Maria Rita

AU - Giaccone, Giorgio

AU - Tagliavini, Fabrizio

AU - Ferrarese, Carlo

AU - Difrancesco, Jacopo C.

PY - 2013/4

Y1 - 2013/4

N2 - Objective: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid-related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti-amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA-ri. Methods: We used a novel ultrasensitive technique on patients from a retrospective multicenter case-control study, and evaluated the anti-Aβ autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA-ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble Aβ40, Aβ42, tau, P-181 tau, and APOE genotype were also investigated. Results: During the acute phase of CAA-ri, anti-Aβ autoantibodies were specifically increased and directly correlated with Aβ mobilization, together with augmented tau and P-181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble Aβ and axonal degeneration markers decreased in parallel. Interpretation: Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ. The CSF dosage of anti-Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti-Aβ autoantibodies can be considered as novel potential biomarkers in future amyloid-modifying therapies for the treatment of AD and CAA.

AB - Objective: Cerebral amyloid angiopathy-related inflammation (CAA-ri) is characterized by vasogenic edema and multiple cortical/subcortical microbleeds, sharing several aspects with the recently defined amyloid-related imaging abnormalities (ARIA) reported in Alzheimer's disease (AD) passive immunization therapies. Herein, we investigated the role of anti-amyloid β (Aβ) autoantibodies in the acute and remission phases of CAA-ri. Methods: We used a novel ultrasensitive technique on patients from a retrospective multicenter case-control study, and evaluated the anti-Aβ autoantibody concentration in the cerebrospinal fluid (CSF) of 10 CAA-ri, 8 CAA, 14 multiple sclerosis, and 25 control subjects. Levels of soluble Aβ40, Aβ42, tau, P-181 tau, and APOE genotype were also investigated. Results: During the acute phase of CAA-ri, anti-Aβ autoantibodies were specifically increased and directly correlated with Aβ mobilization, together with augmented tau and P-181 tau. Following clinical and radiological remission, autoantibodies progressively returned to control levels, and both soluble Aβ and axonal degeneration markers decreased in parallel. Interpretation: Our data support the hypothesis that the pathogenesis of CAA-ri may be mediated by a selective autoimmune reaction against cerebrovascular Aβ, directly related to autoantibody concentration and soluble Aβ. The CSF dosage of anti-Aβ autoantibodies with the technique here described can thus be proposed as a valid alternative tool for the diagnosis of CAA-ri. Moreover, given the similarities between ARIA developing spontaneously and those observed during immunization trials, anti-Aβ autoantibodies can be considered as novel potential biomarkers in future amyloid-modifying therapies for the treatment of AD and CAA.

UR - http://www.scopus.com/inward/record.url?scp=84878407495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878407495&partnerID=8YFLogxK

U2 - 10.1002/ana.23857

DO - 10.1002/ana.23857

M3 - Article

C2 - 23625526

AN - SCOPUS:84878407495

VL - 73

SP - 449

EP - 458

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 4

ER -